Roland D Chapurlat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1539987/publications.pdf Version: 2024-02-01

102	6,420	57758 44	⁶⁶⁹¹¹ 78
papers	citations	h-index	g-index
112	112	112	5828
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Implementation and effectiveness of pharmacist-led interviews at patient hospital admission in a rheumatology department. European Journal of Hospital Pharmacy, 2023, 30, 273-278.	1.1	0
2	The bone strain index predicts fragility fractures. The OFELY study. Bone, 2022, 157, 116348.	2.9	9
3	Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial. Bone, 2022, 157, 116343.	2.9	10
4	Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database. Joint Bone Spine, 2022, 89, 105340.	1.6	2
5	Elevated lipoprotein(a) as a predictor for coronary events in older men. Journal of Lipid Research, 2022, 63, 100242.	4.2	4
6	Reliability and Change in Erosion Measurements by High-resolution Peripheral Quantitative Computed Tomography in a Longitudinal Dataset of Rheumatoid Arthritis Patients. Journal of Rheumatology, 2021, 48, 348-351.	2.0	6
7	Imminent fracture risk. Joint Bone Spine, 2021, 88, 105105.	1.6	10
8	Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis. Osteoporosis International, 2021, 32, 173-184.	3.1	9
9	Bisphosphonates for the treatment of fibrous dysplasia of bone. Bone, 2021, 143, 115784.	2.9	21
10	Reliability of the assessment of disc degeneration on the lateral DXA scans. Joint Bone Spine, 2021, 88, 105123.	1.6	1
11	Of the Futility of Repeating BMD Measurement in Treated Osteoporotic Women. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4784-e4785.	3.6	Ο
12	Bone Microarchitecture Decline and Risk of Fall and Fracture in Men With Poor Physical Performance—The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5180-e5194.	3.6	5
13	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. Journal of Bone and Mineral Research, 2021, 36, 2139-2152.	2.8	35
14	Deterioration of Cortical and Trabecular Microstructure Identifies Women With Osteopenia or Normal Bone Mineral Density at Imminent and Longâ€Term Risk for Fragility Fracture: A Prospective Study. Journal of Bone and Mineral Research, 2020, 35, 833-844.	2.8	33
15	A Signature of Circulating <scp>miRNAs</scp> Associated With Fibrous Dysplasia of Bone: the <scp>mirDys</scp> Study. Journal of Bone and Mineral Research, 2020, 35, 1881-1892.	2.8	10
16	Estimation of Longâ€Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX―and Virtual Twinâ€Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. JBMR Plus, 2020, 4, e10348.	2.7	3
17	High Cardiovascular Risk in Older Men with Poor Bone Microarchitecture—The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2020, 36, 879-891.	2.8	5
18	Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. Journal of Bone and Mineral Research, 2020, 36, 1031-1041.	2.8	9

#	Article	IF	CITATIONS
19	A Novel HR-pQCT Image Registration Approach Reveals Sex-Specific Changes in Cortical Bone Retraction With Aging. Journal of Bone and Mineral Research, 2020, 36, 1351-1363.	2.8	5
20	Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. Journal of Bone and Mineral Research, 2020, 37, 36-40.	2.8	16
21	Bone Microarchitecture Phenotypes Identified in Older Adults Are Associated With Different Levels of Osteoporotic Fracture Risk. Journal of Bone and Mineral Research, 2020, 37, 428-439.	2.8	24
22	Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. Journal of Bone and Mineral Research, 2020, 37, 1136-1146.	2.8	6
23	Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. Journal of Bone and Mineral Research, 2019, 34, 1597-1608.	2.8	98
24	Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet Journal of Rare Diseases, 2019, 14, 139.	2.7	149
25	Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture. PLoS ONE, 2019, 14, e0216947.	2.5	15
26	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 15-24.	2.7	146
27	Relationship Between Sex Steroids and Deterioration of Bone Microarchitecture in Older Men: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2019, 34, 1562-1573.	2.8	16
28	Lack of Association Between Select Circulating miRNAs and Bone Mass, Turnover, and Fractures: Data From the OFELY Cohort. Journal of Bone and Mineral Research, 2019, 34, 1074-1085.	2.8	21
29	Assessment of the clinical relevance of pharmacists' interventions performed during medication review in a rheumatology ward. European Journal of Internal Medicine, 2019, 59, 91-96.	2.2	10
30	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 34-43.	11.4	244
31	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes and Endocrinology,the, 2018, 6, 445-454.	11.4	148
32	Effects and management of denosumab discontinuation. Joint Bone Spine, 2018, 85, 515-517.	1.6	16
33	Utilité du scanner périphérique à haute résolution dans la prise en charge des maladies ostéoarticulaires. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 138-145.	0.0	Ο
34	The QUALYOR (QUalité Osseuse LYon Orléans) study: a new cohort for non invasive evaluation of bone quality in postmenopausal osteoporosis. Rationale and study design. Archives of Osteoporosis, 2018, 13, 2.	2.4	9
35	Contribution of high resolution peripheral quantitative CT to the management of bone and joint diseases. Joint Bone Spine, 2018, 85, 301-306.	1.6	15
36	Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2018, 48, 1-8.	3.4	25

#	Article	IF	CITATIONS
37	Long term prognosis of Scheuermann's disease: The association with fragility fracture - The MINOS cohort. Bone, 2018, 117, 116-122.	2.9	5
38	Least-detectable and age-related local in vivo bone remodelling assessed by time-lapse HR-pQCT. PLoS ONE, 2018, 13, e0191369.	2.5	28
39	Serum Sortilin Associates With Aortic Calcification and Cardiovascular Risk in Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1005-1011.	2.4	44
40	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes and Endocrinology,the, 2017, 5, 513-523.	11.4	635
41	Bone Microarchitecture Assessed by HRâ€pQCT as Predictor of Fracture Risk in Postmenopausal Women: The OFELY Study. Journal of Bone and Mineral Research, 2017, 32, 1243-1251.	2.8	111
42	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2017, 32, 2288-2296.	2.8	7
43	Ostéoporose et maladies cardiovasculaires ischémiques. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 117-122.	0.0	1
44	Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine, 2017, 84, 427-432.	1.6	70
45	Older men with severe disc degeneration have more incident vertebral fractures—the prospective MINOS cohort study. Rheumatology, 2017, 56, 37-45.	1.9	6
46	Regional Differences in Incident Prefrailty and Frailty. Journal of Women's Health, 2017, 26, 992-998.	3.3	2
47	Feasibility of rigid 3D image registration of high-resolution peripheral quantitative computed tomography images of healing distal radius fractures. PLoS ONE, 2017, 12, e0179413.	2.5	14
48	Microarchitecture and Peripheral BMD are Impaired in Postmenopausal White Women With Fracture Independently of Total Hip <i>T</i> -Score: An International Multicenter Study. Journal of Bone and Mineral Research, 2016, 31, 1158-1166.	2.8	69
49	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. Journal of Bone and Mineral Research, 2016, 31, 1466-1472.	2.8	29
50	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. Journal of Bone and Mineral Research, 2016, 31, 940-948.	2.8	508
51	Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study. Journal of Bone and Mineral Research, 2016, 31, 2167-2172.	2.8	37
52	Age-related changes in bone strength from HR-pQCT derived microarchitectural parameters with an emphasis on the role of cortical porosity. Bone, 2016, 83, 233-240.	2.9	57
53	High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. Journal of Rheumatology, 2016, 43, 657-665.	2.0	16
54	Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatology, 2016, 55, 1714-1725.	1.9	81

#	Article	IF	CITATIONS
55	Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?. Joint Bone Spine, 2016, 83, 254-256.	1.6	8
56	In vivo evaluation of bone microstructure in humans: Clinically useful?. BoneKEy Reports, 2016, 5, 813.	2.7	8
57	Erosion or Vascular Channel?. Arthritis and Rheumatology, 2015, 67, 2956-2956.	5.6	12
58	Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 103-109.	2.7	48
59	Trabecular Bone Score: Where are we now?. Joint Bone Spine, 2015, 82, 320-325.	1.6	45
60	Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. Joint Bone Spine, 2014, 81, 549-550.	1.6	37
61	Treatment of postmenopausal osteoporosis with odanacatib. Expert Opinion on Pharmacotherapy, 2014, 15, 559-564.	1.8	12
62	Challenges in longitudinal measurements with HR-pQCT: Evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility. Bone, 2014, 63, 147-157.	2.9	80
63	Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength. Journal of Bone and Mineral Research, 2014, 29, 1786-1794.	2.8	58
64	Risedronate Slows or Partly Reverses Cortical and Trabecular Microarchitectural Deterioration in Postmenopausal Women. Journal of Bone and Mineral Research, 2014, 29, 380-388.	2.8	37
65	Lower serum osteocalcin is associated with more severe metabolic syndrome in elderly men from the MINOS cohort. European Journal of Endocrinology, 2014, 171, 275-283.	3.7	27
66	Association Between Sex Steroid Levels and Bone Microarchitecture in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1400-1410.	3.6	32
67	Bone remodelling in humans is load-driven but not lazy. Nature Communications, 2014, 5, 4855.	12.8	212
68	Fibrous dysplasia and McCune–Albright syndrome: Imaging for positive and differential diagnoses, prognosis, and follow-up guidelines. European Journal of Radiology, 2014, 83, 1828-1842.	2.6	57
69	High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nature Reviews Rheumatology, 2014, 10, 304-313.	8.0	103
70	Emerging drugs for osteoporosis. Expert Opinion on Emerging Drugs, 2014, 19, 385-395.	2.4	19
71	Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker. Joint Bone Spine, 2014, 81, 455-456.	1.6	9
72	Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine, 2014, 81, 175-177.	1.6	26

#	Article	IF	CITATIONS
73	Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4727-4735.	3.6	50
74	Impaired bone microarchitecture at the distal radius in older men with low muscle mass and grip strength: The STRAMBO study. Journal of Bone and Mineral Research, 2013, 28, 169-178.	2.8	50
75	Contribution and limitations of the FRAX® tool. Joint Bone Spine, 2013, 80, 355-357.	1.6	14
76	Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 571-580.	3.6	119
77	Higher Serum Osteocalcin Is Associated With Lower Abdominal Aortic Calcification Progression and Longer 10-Year Survival in Elderly Men of the MINOS Cohort. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1084-1092.	3.6	58
78	Lower fracture risk in older men with higher sclerostin concentration: A prospective analysis from the MINOS study. Journal of Bone and Mineral Research, 2013, 28, 855-864.	2.8	59
79	Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. Journal of Bone and Mineral Research, 2013, 28, 524-536.	2.8	98
80	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS ONE, 2013, 8, e83306.	2.5	63
81	Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. European Journal of Endocrinology, 2012, 166, 735-741.	3.7	37
82	Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. Journal of Bone and Mineral Research, 2012, 27, 825-834.	2.8	96
83	2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine, 2012, 79, 304-313.	1.6	166
84	Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research, 2012, 27, 694-701.	2.8	290
85	Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. Journal of Bone and Mineral Research, 2011, 26, 965-973.	2.8	126
86	Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: The STRAMBO study. Journal of Bone and Mineral Research, 2011, 26, 1358-1367.	2.8	94
87	Predicting fractures in an international cohort using risk factor algorithms without BMD. Journal of Bone and Mineral Research, 2011, 26, 2770-2777.	2.8	58
88	Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. European Journal of Endocrinology, 2011, 165, 647-655.	3.7	47
89	The Ratio 1660/1690 cmâ^'1 Measured by Infrared Microspectroscopy Is Not Specific of Enzymatic Collagen Cross-Links in Bone Tissue. PLoS ONE, 2011, 6, e28736.	2.5	74
90	The FRAX tool in French women: How well does it describe the real incidence of fracture in the OFELY cohort. Journal of Bone and Mineral Research, 2010, 25, 2101-2107.	2.8	91

#	Article	IF	CITATIONS
91	Association between bone turnover rate and bone microarchitecture in men: The STRAMBO study. Journal of Bone and Mineral Research, 2010, 25, 2313-2323.	2.8	67
92	Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. Bone, 2010, 46, 1030-1037.	2.9	153
93	Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture. Therapeutics and Clinical Risk Management, 2009, 5, 169.	2.0	3
94	Mechanisms of the Anabolic Effects of Teriparatide on Bone: Insight From the Treatment of a Patient With Pycnodysostosis. Journal of Bone and Mineral Research, 2008, 23, 1076-1083.	2.8	56
95	Fibrous dysplasia of bone and McCune–Albright syndrome. Best Practice and Research in Clinical Rheumatology, 2008, 22, 55-69.	3.3	186
96	Single annual injectable treatment for postmenopausal osteoporosis. Expert Opinion on Drug Delivery, 2008, 5, 583-591.	5.0	2
97	Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study. Journal of Bone and Mineral Research, 2007, 22, 1502-1509.	2.8	135
98	Medical Therapy in Adults With Fibrous Dysplasia of Bone. Journal of Bone and Mineral Research, 2006, 21, P114-P119.	2.8	120
99	Review of ibandronate in the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 2003, 4, 391-396.	1.8	6
100	Fibrous dysplasia of bone. Best Practice and Research in Clinical Rheumatology, 2000, 14, 385-398.	3.3	96
101	Serum Estradiol and Sex Hormone-Binding Globulin and the Risk of Hip Fracture in Elderly Women: The EPIDOS Study. Journal of Bone and Mineral Research, 2000, 15, 1835-1841.	2.8	94
102	Long-Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of Bone. Journal of Bone and Mineral Research, 1997, 12, 1746-1752.	2.8	208